↓ Skip to main content

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Overview of attention for article published in Clinical Cancer Research, November 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
6 news outlets
blogs
1 blog
twitter
1 tweeter
patent
7 patents
wikipedia
8 Wikipedia pages
f1000
1 research highlight platform

Citations

dimensions_citation
362 Dimensions

Readers on

mendeley
449 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Published in
Clinical Cancer Research, November 2011
DOI 10.1158/1078-0432.ccr-11-1595
Pubmed ID
Authors

Evan J. Lipson, Charles G. Drake

Abstract

Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overall survival: Median overall survival was 10.1 and 10.0 months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 6.4 months in the vaccine-alone group (hazard ratio, 0.68; P ≤ 0.003). Serious (grade 3-5) immune-related adverse events occurred in 10% to 15% of patients. Thus, although it provides a clear survival benefit, ipilimumab administration requires careful patient monitoring and sometimes necessitates treatment with immune-suppressive therapy. Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 449 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 <1%
United Kingdom 3 <1%
Ecuador 1 <1%
South Africa 1 <1%
Japan 1 <1%
Denmark 1 <1%
Unknown 438 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 78 17%
Student > Ph. D. Student 68 15%
Student > Master 58 13%
Researcher 55 12%
Other 34 8%
Other 79 18%
Unknown 77 17%
Readers by discipline Count As %
Medicine and Dentistry 101 22%
Agricultural and Biological Sciences 87 19%
Biochemistry, Genetics and Molecular Biology 79 18%
Immunology and Microbiology 33 7%
Chemistry 15 3%
Other 48 11%
Unknown 86 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 73. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2022.
All research outputs
#498,921
of 22,899,952 outputs
Outputs from Clinical Cancer Research
#299
of 12,611 outputs
Outputs of similar age
#1,916
of 141,881 outputs
Outputs of similar age from Clinical Cancer Research
#1
of 129 outputs
Altmetric has tracked 22,899,952 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,611 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 141,881 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 129 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.